$>A7;/: F 7

22
& !%( % !!"! "! $ & $>A7;/: <A35?/A7=< =4 63;=A63?/>F 7<A= A63 "/</53;3<A =4 "3A/@A/A71 %?=@A/A3 /<13?

Transcript of $>A7;/: F 7

Page 1: $>A7;/: F 7
Page 2: $>A7;/: F 7
Page 3: $>A7;/: F 7
Page 4: $>A7;/: F 7
Page 5: $>A7;/: F 7
Page 6: $>A7;/: F 7
Page 7: $>A7;/: F 7
Page 8: $>A7;/: F 7
Page 9: $>A7;/: F 7

STAMPEDEComparisonOpen: Oct-2005Closed: Mar-2013Accrual: 2962

Number of patients1184 A Standard-of-care (SOC)593 B SOC + zoledronic acid592 C SOC + docetaxel593 E SOC + zoledronic acid + docetaxel

Page 10: $>A7;/: F 7

Docetaxel: Survival – M1 Patients

Page 11: $>A7;/: F 7
Page 12: $>A7;/: F 7
Page 13: $>A7;/: F 7
Page 14: $>A7;/: F 7
Page 15: $>A7;/: F 7
Page 16: $>A7;/: F 7
Page 17: $>A7;/: F 7
Page 18: $>A7;/: F 7
Page 19: $>A7;/: F 7

Robinson Cell 161:1215, 2015

23%

Page 20: $>A7;/: F 7

Mateo NEJM 373:1697, 2015

Page 21: $>A7;/: F 7
Page 22: $>A7;/: F 7

Local Therapy

Androgen Deprivation

Therapies After LHRH Agonists

and Antiandrogens

Chemotherapy

Postchemotherapy

Death

motherapa

PostchemP t hP h